[1]胡欣,陈国芳,刘超.抗肿瘤药物对甲状腺功能的影响[J].国际内分泌代谢杂志,2017,37(01):27-31.[doi:10.3760/cma.j.issn.1673-4157.2017.01.08]
　Hu Xin,Chen Guofang,Liu Chao..Effects of antineoplastic agents on thyroid function[J].International Journal of Endocrinology and Metabolism,2017,37(01):27-31.[doi:10.3760/cma.j.issn.1673-4157.2017.01.08]
点击复制

抗肿瘤药物对甲状腺功能的影响()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
37
期数:
2017年01期
页码:
27-31
栏目:
综述
出版日期:
2017-01-20

文章信息/Info

Title:
Effects of antineoplastic agents on thyroid function
作者:
胡欣; 陈国芳; 刘超
210028 南京中医药大学附属中西医结合医院内分泌代谢病院区,江苏省中医药研究院,中国中医科学院江苏分院
Author(s):
Hu Xin;  Chen Guofang;  Liu Chao.
Endocrine and Diabetes Center, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Jiangsu Province Academy of Traditional Chinese Medicine, Jiangsu Branch of China Academy of Chinese Medical
关键词:
抗肿瘤药物;  甲状腺功能;  药物治疗
Keywords:
Antineoplastic agents;  Thyroid dysfunction;  Drug therapy
DOI:
10.3760/cma.j.issn.1673-4157.2017.01.08
摘要:
近年发现,基于靶向治疗及免疫治疗的新型抗肿瘤治疗与甲状腺功能之间存在着诸多联系。大多数药物可导致20%～50%的患者出现甲状腺功能异常,但易被忽略。甲状腺病变不仅可能对原发病或抗肿瘤药物产生影响,而且亦会降低患者的生活质量。对个别患者而言,甲状腺疾病可能是预测肿瘤对药物反应的指标。因此,建议对接受抗肿瘤药物治疗的患者常规监测甲状腺功能的变化,并制定个体化的治疗方案。
Abstract:
It has been found that new antineoplastic agents such as targeted therapies and immunotherapies are closely associated with thyroid dysfunction. Most agents cause thyroid dysfunction in 20%-50% of patients, but it is easily overlooked. Thyroid disorders may not only affect the primary disease or the antineoplastic agent, but also adversely affects the patient's quality of life. In some patients, thyroid disease may indicate response of tumor to the antineoplastic agent. Therefore routine testing is recommended for thyroid abnormalities in patients receiving antineoplastic agents, furthermore, the individual management is established.

参考文献/References:

[1] Lele AV, Clutter S, Price E, et al. Severe hypothyroidism presenting as myxedema coma in the postoperative period in a patient taking sunitinib: case report and review of literature[J].J Clin Anesth,2013,25(1):47-51.DOI: 10.1016/j.jclinane.2012.07.001.
[2] Collinson FJ, Vasudev NS, Berkin L, et al. Sunitinib-induced severe hypothyroidism with cardiac compromise[J].Med Oncol,2011,Suppl 1:S699-S701. DOI: 10.1007/s12032-010-9757-z.
[3] Schmidinger M, Vogl UM, Bojic M, et al. Hypothyroidism in patients with renal cell carcinoma: blessing or curse[J]. Cancer,2011,117(3):534-544. DOI: 10.1002/cncr.25422.
[4] Liu H, Jian Q, Xue K, et al. The MEK/ERK signalling cascade is required for sonic hedgehog signalling pathway-mediated enhancement of proliferation and inhibition of apoptosis in normal keratinocytes[J].Exp Dermatol,2014,23(12):896-901. DOI: 10.1111/exd.12556.
[5] Abdulrahman RM, Verloop H, Hoftijzer H,et al. Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination[J].J Clin Endocrinol Metab,2010,95(8):3758-3762. DOI: 10.1210/jc.2009-2507.
[6] Fallahi P, Ferrari SM, Vita R, et al. Thyroid dysfunctions induced by tyrosine kinase inhibitors[J].Expert Opin Drug Saf,2014,13(6):723-733. DOI: 10.1517/14740338.2014.913021.
[7] Lodish MB, Stratakis CA. Endocrine side effects of broad-acting kinase inhibitors[J].Endocr Relat Cancer,2010,17(3):R233-R244. DOI: 10.1677/ERC-10-0082.
[8] Kim TD, Schwarz M, Nogai H, et al. Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia[J].Thyroid,2010,20(11):1209-1214. DOI: 10.1089/thy.2010.0251.
[9] Mukohara T, Nakajima H, Mukai H,et al. Effect of axitinib(AG-013736)on fatigue, thyroid-stimulating hormone, and biomarkers: a phase Ⅰ study in Japanese patients[J].Cancer Sci,2010,101(4):963-968. DOI: 10.1111/j.1349-7006.2009.01465.x.
[10] Rogiers A, Wolter P, Op de Beeck K, et al. Shrinkage of thyroid volume in sunitinib-treated patients with renal-cell carcinoma: a potential marker of irreversible thyroid dysfunction.Thyroid,2010,20(3):317-322. DOI: 10.1089/thy.2009.0125.
[11] Haugen BR. Drugs that suppress TSH or cause central hypothyroidism[J].Best Pract Res Clin Endocrinol Metab,2009,23(6):793-800. DOI: 10.1016/j.beem.2009.08.003.
[12] Duvic M, Geskin L, Prince HM. Duration of response in cutaneous T-cell lymphoma patients treated with denileukin diftitox: results from 3 phase Ⅲ studies[J].Clin Lymphoma Myeloma Leuk,2013,13(4):377-384. DOI: 10.1016/j.clml.2013.02.020.
[13] Ghori F, Polder KD, Pinter-Brown LC, et al. Thyrotoxicosis after denileukin diftitox therapy in patients with mycosis fungoides[J].J Clin Endocrinol Metab, 2006,91(6):2205-2208.DOI:10.1210/jc.2005-2839.
[14] Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial[J].Lancet,2012,380(9856):1819-1828. DOI: 10.1016/S0140-6736(12)61769-3.
[15] Mammen JS, Ghazarian SR, Pulkstenis E, et al. Phenotypes of interferon-α-induced thyroid dysfunction among patients treated for hepatitis C are associated with pretreatment serum TSH and female sex[J].J Clin Endocrinol Metab,2012,97(9):3270-3276. DOI: 10.1210/jc.2012-1026.
[16] Hamnvik OP, Larsen PR, Marqusee E. Thyroid dysfunction from antineoplastic agents[J].J Natl Cancer Inst,2011,103(21):1572-1587. DOI: 10.1093/jnci/djr373.
[17] Faje AT, Sullivan R, Lawrence D, et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma[J].J Clin Endocrinol Metab,2014,99(11):4078-4085. DOI: 10.1210/jc.2014-2306.
[18] Mateos MV. Management of treatment-related adverse events in patients with multiple myeloma[J].Cancer Treat Rev,2010,36(Suppl 2):S24-S32. DOI: 10.1016/S0305-7372(10)70009-8.
[19] Kastritis E, Terpos E, Roussou M,et al. A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone(RdC)in AL amyloidosis[J].Blood,2012,119(23):5384-5390. DOI: 10.1182/blood-2011-12-396903.
[20] Torino F, Barnabei A, Paragliola R, et al. Thyroid dysfunction as an unintended side effect of anticancer drugs[J].Thyroid,2013,23(11):1345-1366. DOI: 10.1089/thy.2013.0241.

相似文献/References:

[1]孙盟朝 乔潇 王帆 梁钰涵 乔欣 陈钊 张媛 林来祥.哺乳期大鼠甲状腺功能及自身抗体变化的研究[J].国际内分泌代谢杂志,2015,(05):289.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.001]
　Sun Mengzhao*,Qiao Xiao,Wang Fan,et al.Changes in thyroid function and autoantibodies during lactation of rats[J].International Journal of Endocrinology and Metabolism,2015,(01):289.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.001]
[2]邱俊霖.糖尿病酮症酸中毒患者甲状腺功能状态分析[J].国际内分泌代谢杂志,2017,37(06):376.
　Qiu Junlin..Analysis of thyroid function in patients with diabetic ketoacidosis[J].International Journal of Endocrinology and Metabolism,2017,37(01):376.

备注/Memo

备注/Memo:
通信作者:刘超,Email:liuchao@nfmcn.com
更新日期/Last Update: 2017-01-20